The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes in your immune system.

开始日期2014-05-01

申办/合作机构

University of Virginia

[+1]

100 项与 Long Peptide Vaccine LPV7(University of Virginia Foundation) 相关的临床结果

登录后查看更多信息

100 项与 Long Peptide Vaccine LPV7(University of Virginia Foundation) 相关的转化医学

登录后查看更多信息

100 项与 Long Peptide Vaccine LPV7(University of Virginia Foundation) 相关的专利（医药）

登录后查看更多信息

项与 Long Peptide Vaccine LPV7(University of Virginia Foundation) 相关的文献（医药）

2021-08-01·Journal for ImmunoTherapy of Cancer2区 · 医学

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

2区 · 医学

ArticleOA

作者: Varhegyi, Nikole ; Smolkin, Mark ; Petroni, Gina R ; Patel, Sapna P ; Gnjatic, Sacha ; Hwu, Patrick ; Gaughan, Elizabeth ; Smith, Kelly T ; Wages, Nolan A ; Roszik, Jason ; Slingluff, Craig L ; Chianese-Bullock, Kimberly A ; Olson, Walter C ; Haden, Kathleen ; Hall, Emily H

BackgroundWe performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund’s adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7/8 (resiquimod). We hypothesized that T cell responses to minimal epitope peptides (MEPs) within the long peptides would be enhanced compared with prior vaccines with MEP themselves and that T cell responses would be enhanced with TLR agonists, compared with IFA alone.MethodsParticipants with resected stage IIB-IV melanoma were vaccinated with seven long melanoma peptides (LPV7) from tyrosinase, gp100, MAGE-A1, MAGE-A10, and NY-ESO-1, each containing a known MEP for CD8+T cells, plus a tetanus helper peptide (Tet) restricted by Class II MHC. Enrollment was guided by an adaptive design to one of seven adjuvant combinations. Vaccines were administered at weeks 1, 2, 3, 6, 9, 12 at rotating injection sites. T cell and IgG antibody (Ab) responses were measured with IFN-gamma ELIspot assay ex vivo and ELISA, respectively.ResultsFifty eligible participants were assigned to seven study groups, with highest enrollment on arm E (LPV7+Tet+IFA+polyICLC). There was one dose-limiting toxicity (DLT) in Group E (grade 3 injection site reaction, 6% DLT rate). All other treatment-related adverse events were grades 1–2. The CD8+T cell immune response rate (IRR) to MEPs was 18%, less than in prior studies using MEP vaccines in IFA. The CD8+T cell IRR trended higher for IFA-containing adjuvants (24%) than adjuvants containing only TLR agonists (6%). Overall T cell IRR to full-length LPV7 was 30%; CD4+T cell IRR to Tet was 40%, and serum Ab IRR to LPV7 was 84%. These IRRs also trended higher for IFA-containing adjuvants (36% vs 18%, 48% vs 24%, and 97% vs 60%, respectively).ConclusionsThe LPV7 vaccine is safe with each of seven adjuvant strategies and induced T cell responses to CD8 MEPs ex vivo in a subset of patients but did not enhance IRRs compared with prior vaccines using short peptides. Immunogenicity was supported more by IFA than by TLR agonists alone and may be enhanced by polyICLC plus IFA.Trial registration numberNCT02126579.

100 项与 Long Peptide Vaccine LPV7(University of Virginia Foundation) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黑色素瘤	临床2期	-	University of Virginia Foundation	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02126579 (MEL60, CTgov)	临床1/2期	黏膜黑色素瘤 \| 转移性黑色素瘤	50	IFA+Peptide Vaccine (LPV7) (Arm A (Part 1))	蓋齋鑰觸壓鹹網遞艱鑰(製積衊繭窪衊製觸願蓋) = 夢網衊選齋簾鬱廠積鏇鏇膚網糧鹽觸淵構鑰鑰 (廠積廠顧鏇積簾選願廠, 築壓製觸鏇衊廠廠艱獵 ~ 製廠願鑰網鑰構積獵鏇) 更多	-	2023-11-03
NCT02126579 (MEL60, CTgov)	临床1/2期	黏膜黑色素瘤 \| 转移性黑色素瘤	50	PolyICLC+Peptide Vaccine (LPV7) (Arm B (Part 1))	蓋齋鑰觸壓鹹網遞艱鑰(製積衊繭窪衊製觸願蓋) = 製窪繭網艱衊獵鬱鹹繭鏇膚網糧鹽觸淵構鑰鑰 (廠積廠顧鏇積簾選願廠, 願襯鹽鹹範憲衊積齋鹽 ~ 鏇餘醖鬱醖鏇襯願餘網) 更多	-	2023-11-03
NCT02126579 (MEL60, pubmed \| J Immunother Cancer) 人工标引	临床1/2期	黑色素瘤辅助	50	TLR agonists+LPV7	(糧窪糧壓膚蓋糧糧鏇膚) = 遞艱淵顧顧壓鏇齋憲顧鹽夢襯獵鏇範構鏇網鹽 (顧築鹽觸膚憲餘醖鑰窪 )	积极	2021-08-01